Area riservata
Wiki Oncologia
- Le varianti di un solo gene all’origine dei tumori della pelle e del glioma
- Identificata all’Istituto Gaslini una nuova strategia per il trattamento dei tumori polmonari
- Studio IARC: molti tumori hanno origine dalle infezioni
- Tumore: una patologia sempre più cronica e di massa. Preoccupano le differenze regionali nelle opportunità di cura per i pazienti
- Tumore del seno: “Serve uno screening personalizzato. Mammografia anche alle quarantenni e alle over 70”
- Efficacia della radioterapia intraoperatoria nel carcinoma prostatico
- Una foto dell'epi-genoma per la terapia personalizzata dei tumori
- Nello Zebrafish il modello per colpire Ras, un gene alla base di tumori e malattie genetiche
- Modelli molecolari per predire quale farmaco può meglio funzionare nella cura di alcuni tumori
- Istituto Regina Elena: dalla ricerca di laboratorio una nuova arma per la lotta contro il carcinoma ovarico
A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors |
Scritto da Annals of Oncology - current issue |
![]() There are limited data about the quality of immune-related adverse event (irAE) reporting in immune checkpoint inhibitor (ICI) clinical trial publications. MethodsA systematic search of citations from Medline, EMBASE and Cochrane databases identified prospective clinical trials involving ICIs in advanced solid tumors from 2003 to 2013. A 21-point quality score (QS) was adapted from the CONSORT harms extension statement. Linear regression was used to identify factors associated with quality reporting. ResultsAfter a review of 2628 articles, 50 trial reports were included, with ICIs as either monotherapy (54%) or part of a combination regimen (46%). The mean QS was 11.21 points (range 3.50–17.50 points). The median grade 3/4 AE rate reported was 21% (range 0%–66%) and 29/50 (58%) trials concluded that irAEs were tolerable. Multivariate regression analysis revealed that year of publication (within last 5 years, P = 0.01) and journal impact factor >15 (P = 0.004) were associated with higher QS. Complete reporting of specific characteristics of irAEs including onset, management and reversibility were reported by 14%, 8% and 6% of studies, respectively. The incidence of grade 3/4 adverse events was higher for inhibitors against CTLA-4 compared with other immune checkpoints (P Conclusions The reporting of irAEs is suboptimal. A standardized reporting method of irAEs that accounts for tolerability, management and reversibility is needed and would enable a more precise evaluation of the therapeutic risk benefit ratio of ICIs. Fonte: Annals of Oncology - current issue |